ArticleClinical and translational radiation oncology2026
Long-term Outcomes of Toxicities and Disease Control Following Postoperative Moderately Hypofractionated Radiotherapy in High-Risk Prostate Cancer: Results of a Prospective Study.
Article in Clinical and translational radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Moderately hypofractionated radiation therapy (MHRT) offers practical advantages for postoperative prostate cancer (PC) patients. However, concerns persist regarding long-term genitourinary (GU) toxicity. This prospective cohort study aims to evaluate late toxicities, disease control outcomes, and to identify predictors of late GU toxicity following MHRT. Methods: We prospectively enrolled 278 PC patients treated with postoperative MHRT (62.75 Gy delivered in 25 fractions) at our institution from 2018 to 2020. Late GU and gastrointestinal (GI) toxicities were graded using CTCAE v.4.0. Clinical outcomes were analyzed, including event-free survival (EFS), biochemical progression-free survival (bPFS), disease-specific survival (DSS), and overall survival (OS). Univariate and multivariate Cox regression analyses were performed to identify predictors associated with late GU toxicity. Results: The median follow-up was 50 months. The cumulative incidence of late grade ≥ 2 GU toxicity at 2 and 4 years was 19.5% and 28.4%, respectively. Patients with bladder V Conclusions: Postoperative MHRT for PC demonstrates acceptable toxicity and promising efficacy. However, late GU toxicities continue to evolve beyond the 2-year period. Our findings identify key predictors: limiting bladder V
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.